Results 31 to 40 of about 2,519,772 (150)
Fibrates for Primary Biliary Cholangitis: What’s All the Hype?
Annals of Hepatology, 2017 Ursodeoxycholic acid is the first-line therapy for primary biliary cholangitis. However, a subset of patients fail to show biochemical response. For these patients, adjuvant therapies are warranted. Obeticholic acid was conditionally approved as a second-
Cynthia Levy
doaj +1 more source
Anti-Cholestatic Therapy with Obeticholic Acid Improves Short-Term Memory in Bile Duct-Ligated Mice. [PDF]
Am J Pathol, 2023 Cholestatic liver disease patients, including those with primary biliary cholangitis, can experience symptoms of impaired cognition or “brain fog”. This phenomenon remains unexplained and is currently untreatable.
Gee LMV +33 more
europepmc +3 more sources
A Novel Telescoped Kilogram-Scale Process for Preparation of Obeticholic Acid
Pharmaceutical Fronts, 2021 A novel scalable four-step process has been developed to improve the synthesis of obeticholic acid (OCA). The key step of this process was the isolation of the amide intermediate, which underwent hydrogenation, basic epimerization, ketone reduction, and ...
Cheng-Wei Li +4 more
doaj +1 more source
Farnesoid X receptor (FXR): Structures and ligands
Computational and Structural Biotechnology Journal, 2021 Farnesoid X receptor (FXR) is a bile acid activated nuclear receptor (BAR) and is mainly expressed in the liver and intestine. Upon ligand binding, FXR regulates key genes involved in the metabolic process of bile acid synthesis, transport and ...
Longying Jiang +4 more
doaj +1 more source
Can Pharmacologic Therapy Induce Histologic Improvement in Non-alcoholic Steatohepatitis?
The Korean Journal of Gastroenterology, 2016 Articles: Farnesoid X Nuclear Receptor Ligand Obeticholic Acid for Non-cirrhotic, Non-alcoholic Steatohepatitis (FLINT): a Multicentre, Randomised, Placebo-controlled Trial (Lancet 2015;385:956-965) Liraglutide Safety and Efficacy in Patients with Non ...
Nae-Yun Heo
doaj +1 more source
miR-22 inhibition reduces hepatic steatosis via FGF21 and FGFR1 induction
JHEP Reports, 2020 Background & Aims: Metabolism supports cell proliferation and growth. Surprisingly, the tumor suppressor miR-22 is induced by metabolic stimulators like bile acids. Thus, this study examines whether miR-22 could be a metabolic silencer.
Ying Hu +5 more
doaj +1 more source
RP-HPLC analytical method development and validation of obeticholic acid in bulk and marketed formulation [PDF]
, 2022 The purpose of this study is to develop a new analytical RP-HPLC method for quantifying Obeticholic Acid in bulk and commercial formulations. Liquid chromatography is performed on a C18 column and the mobile phase is prepared using 0.1% orthophosphoric ...
Avhad, Pawan S., Gupta, Revathi
core +1 more source
Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
Acta Pharmaceutica Sinica B, 2019 Obeticholic acid (OCA), the first FXR-targeting drug, has been claimed effective in the therapy of liver fibrosis. However, recent clinical trials indicated that OCA might not be effective against liver fibrosis, possibly due to the lower dosage to ...
Jiyu Zhou +9 more
doaj +1 more source
Impact of Primary and Secondary Bile Acids on Clostridioides difficile Infection
Polish Journal of Microbiology, 2022 Primary bile acids (BAs), synthesized from cholesterol in the liver, after their secretion with bile into the intestinal lumen, are transformed by gut microbiota to secondary BAs. As natural detergents, BAs play a key role in the digestion and absorption
Łukawska Agata, Mulak Agata
doaj +1 more source
Advanced Science, EarlyView.ABSTRACT Bile acids have been implicated in calcium oxalate (CaOx) nephrolithiasis. Here, we employ multi‐omics approaches to identify isoallolithocholic acid (isoalloLCA) as the key bile acid elevated in the feces, serum, kidney, and urine of CaOx rats, confirmed by spatial metabolomics.
Zijian Zhou +9 more
wiley +1 more source